Galderma Group AG (SWX:GALD)

Market Cap	31.01B
Revenue (ttm)	3.73B
Net Income (ttm)	300.62M
Shares Out	237.41M
EPS (ttm)	1.26
PE Ratio	103.31
Forward PE	46.89
Dividend	0.15 (0.11%)
Ex-Dividend Date	Apr 25, 2025

Volume	37,386
Average Volume	1,340,194
Open	130.80
Previous Close	130.60
Day's Range	129.90 - 131.50
52-Week Range	72.70 - 138.80
Beta	n/a
RSI	58.19
Earnings Date	Jul 24, 2025

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Actinica, Dysport/Azzalure, Alluzience, Restylane and Restylane Skinboosters, Sculptra, Cetaphil and Alastin, Soolantra, Epiduo and Epiduo Forte, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Mirvaso, Nemluvio, Relfydess, Benzac, Loceryl, and TRI-LUMA in ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 6,545
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

Financial numbers in USD